Corredores Jamel, Hemo Itzhak, Jaouni Tareq, Habot-Wilner Zohar, Kramer Michal, Shulman Shiri, Jabaly-Habib Haneen, Al-Talbishi Ala'a, Halpert Michael, Averbukh Edward, Levy Jaime, Deitch-Harel Iris, Amer Radgonde
Department of Ophthalmology, Hadassah Medical Center, Jerusalem 91240, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Avi 6997801, Israel.
Int J Ophthalmol. 2021 Jan 18;14(1):97-105. doi: 10.18240/ijo.2021.01.14. eCollection 2021.
To analyze the risk factors, ophthalmological features, treatment modalities and their effect on the visual outcome in patients with endogenous fungal endophthalmitis (EFE).
Data retrieved from the medical files included age at presentation to the uveitis clinic, gender, ocular symptoms and their duration before presentation, history of fever, eye affected, anatomical diagnosis and laboratory evidence of fungal infection. Medical therapy recorded included systemic antifungal therapy and its duration, use of intravitreal antifungal agents and use of oral/intravitreal steroids. Surgical procedures and the data of ophthalmologic examination at presentation and at last follow-up were also collected.
Included were 13 patients (20 eyes, mean age 58y). Ten patients presented after gastrointestinal or urological interventions and two presented after organ transplantation. In one patient, there was no history of previous intervention. Diagnostic vitrectomy was performed in 16 eyes (80%) and vitreous cultures were positive in 10 of the vitrectomized eyes (62.5%). In only 4 patients (31%), blood cultures were positive. All patients received systemic antifungal therapy. Sixteen eyes (80%) received intravitreal antifungal agent with voriconazole being the most commonly used. Visual acuity (VA) improved from 0.9±0.9 at initial exam to 0.5±0.8 logMAR at last follow-up (=0.03). A trend of greater visual improvement was noted in favor of eyes treated with oral steroids (±intravitreal dexamethasone) than eyes that were not treated with steroids. The most common complication was maculopathy. Twelve eyes (60%) showed no ocular complications.
High index of suspicion in patients with inciting risk factors is essential because of the low yield of blood cultures and the good general condition of patients at presentation. Visual prognosis is improved with the prompt institution of systemic and intravitreal pharmacotherapy and the immediate surgical intervention. Oral±local steroids could be considered in cases of prolonged or marked inflammatory responses in order to hasten control of inflammation and limit ocular complications.
分析内源性真菌性眼内炎(EFE)患者的危险因素、眼科特征、治疗方式及其对视力预后的影响。
从病历中检索的数据包括到葡萄膜炎门诊就诊时的年龄、性别、眼部症状及其出现前的持续时间、发热史、受累眼、解剖学诊断以及真菌感染的实验室证据。记录的药物治疗包括全身抗真菌治疗及其持续时间、玻璃体内抗真菌药物的使用以及口服/玻璃体内类固醇的使用。还收集了手术过程以及就诊时和最后一次随访时的眼科检查数据。
纳入13例患者(20只眼,平均年龄58岁)。10例患者在胃肠道或泌尿外科手术后就诊,2例在器官移植后就诊。1例患者无既往干预史。16只眼(80%)进行了诊断性玻璃体切除术,其中10只接受玻璃体切除的眼(62.5%)玻璃体培养呈阳性。仅4例患者(31%)血培养呈阳性。所有患者均接受全身抗真菌治疗。16只眼(80%)接受了玻璃体内抗真菌药物治疗,其中伏立康唑是最常用的药物。视力(VA)从初次检查时的0.9±0.9提高到最后一次随访时的0.5±0.8 logMAR(P=0.03)。与未接受类固醇治疗的眼相比,接受口服类固醇(±玻璃体内地塞米松)治疗的眼视力改善趋势更明显。最常见的并发症是黄斑病变。12只眼(60%)未出现眼部并发症。
由于血培养阳性率低且患者就诊时一般状况良好,对于有诱发危险因素的患者,高度怀疑至关重要。及时进行全身和玻璃体内药物治疗以及立即进行手术干预可改善视力预后。对于炎症反应持续时间长或明显的病例,可考虑使用口服±局部类固醇,以加速炎症控制并减少眼部并发症。